Abstract for MIV-818 phase 1b monotherapy for ESMO Congress published
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that the Abstract entitled “Phase 1 study of the novel prodrug MIV-818 in patients with hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA) or liver metastases (LM)” has been released on the European Society for Medical Oncology (ESMO) website . The results from the completed phase 1b monotherapy dose escalation part of the study will be presented byDr Debashis Sarker, King´s College, London, as an e-poster (number 527P) at ESMO on Thursday